⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 4, 2024

Table S4 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger Meredith McKean Rizwan Haq J. Thaddeus Beck Matthew H. Taylor Jonathan Cohen Daniel W. Bowles Shirish M. Gadgeel Catalin Mihalcioiu Kyriakos P. Papadopoulos Eli L. Diamond Keren Sturtz Gang Feng Stefanie K. Drescher Micaela B. Reddy Bhaswati Sengupta Arnab K. Maity Suzy A. Brown Anurag Singh Eric N. Brown Brian R. Baer Jim Wong Tung‐Chung Mou Wen‐I Wu D Kahn Sunyana Gadal Neal Rosen John J. Gaudino Patrice A. Lee Dylan P. Hartley S. Michael Rothenberg

View at Publisher

Ask AI

Bookmark

Share

Abstract

Table S4. Treatment-Emergent Adverse Events (≥3 patients) with PF-07799933 monotherapy and combination therapy

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yaeger et al. (2024) studied this question.

synapsesocial.com/papers/68e5968ab6db643587531296 https://doi.org/10.1158/2159-8290.26935041.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S4 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation2024
2Table S3 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation2024
3Table S3 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation2024
4Figure S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation2024
5Table S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation2024